Sign in Subscribe
Stock offerings

Senseonics Holdings Announces Pricing of $50 Million Underwritten Public Offering

Strategic Insights

— 2 min read

Senseonics Holdings, Inc. has announced the pricing of a $50 million underwritten public offering of 100 million shares of common stock at $0.50 per share. The offering is expected to close on May 19, 2025, subject to satisfaction of customary closing conditions. The gross proceeds to Senseonics from the offering are expected to be $50 million, before deducting underwriting discounts and commissions and estimated offering expenses.

TD Cowen and Barclays are acting as joint book-running managers and RBC Capital Markets and Lake Street are acting as bookrunners for the proposed offering. The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus that was originally filed with the Securities and Exchange Commission (SEC) on August 10, 2023 and became effective on September 12, 2023.

Senseonics intends to use the net proceeds from the public offering and a concurrent private placement with Abbott Laboratories to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes.

About Senseonics, Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.

Key Takeaways:

  • Senseonics Holdings, Inc. has priced a $50 million underwritten public offering of 100 million shares of common stock at $0.50 per share.
  • The offering is expected to close on May 19, 2025, subject to satisfaction of customary closing conditions.
  • TD Cowen and Barclays are acting as joint book-running managers and RBC Capital Markets and Lake Street are acting as bookrunners for the proposed offering.
  • Senseonics intends to use the net proceeds from the public offering and a concurrent private placement with Abbott Laboratories to fund the ongoing launch of Eversense 365 and continued development of pipeline products.
  • The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus that was originally filed with the SEC on August 10, 2023 and became effective on September 12, 2023.
  • Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products.

Statistics:

  • 100 million shares of common stock to be sold at $0.50 per share.
  • Expected gross proceeds of $50 million before deducting underwriting discounts and commissions and estimated offering expenses.
  • $0.50 per share offering price.
  • May 19, 2025, expected closing date.
  • 30-day option to purchase up to an additional 15 million shares of common stock at the public offering price, less underwriting discounts and commissions.

Sources:

  • Senseonics Holdings, Inc. press release, dated May 17, 2025.
  • Securities and Exchange Commission (SEC) website.
  • Senseonics Holdings, Inc. Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025.
  • Senseonics Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025.

Read more